DK0763529T3 - Uracilderivater og antitumorvirkningspotentiator og antitumormiddel indeholdende samme - Google Patents
Uracilderivater og antitumorvirkningspotentiator og antitumormiddel indeholdende sammeInfo
- Publication number
- DK0763529T3 DK0763529T3 DK96907693T DK96907693T DK0763529T3 DK 0763529 T3 DK0763529 T3 DK 0763529T3 DK 96907693 T DK96907693 T DK 96907693T DK 96907693 T DK96907693 T DK 96907693T DK 0763529 T3 DK0763529 T3 DK 0763529T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- lower alkyl
- substituted
- hydrogen atom
- alkyl group
- Prior art date
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 7
- -1 methanesulfonyloxy, amino Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 abstract 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Organic Insulating Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7166795 | 1995-03-29 | ||
| PCT/JP1996/000828 WO1996030346A1 (en) | 1995-03-29 | 1996-03-28 | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0763529T3 true DK0763529T3 (da) | 2003-11-10 |
Family
ID=13467185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96907693T DK0763529T3 (da) | 1995-03-29 | 1996-03-28 | Uracilderivater og antitumorvirkningspotentiator og antitumormiddel indeholdende samme |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US5744475A (da) |
| EP (1) | EP0763529B1 (da) |
| JP (1) | JP3088757B2 (da) |
| KR (1) | KR100424934B1 (da) |
| AT (1) | ATE245631T1 (da) |
| AU (1) | AU681321B2 (da) |
| CA (1) | CA2191340C (da) |
| DE (1) | DE69629156T2 (da) |
| DK (1) | DK0763529T3 (da) |
| ES (1) | ES2203683T3 (da) |
| HU (1) | HU227726B1 (da) |
| NO (1) | NO308033B1 (da) |
| PT (1) | PT763529E (da) |
| WO (1) | WO1996030346A1 (da) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0763529B1 (en) | 1995-03-29 | 2003-07-23 | Taiho Pharmaceutical Company Limited | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
| PT884051E (pt) * | 1996-09-24 | 2005-03-31 | Taiho Pharmaceutical Co Ltd | Inibidores de metasteses cancerosas contendo derivados de uracilo |
| US6235776B1 (en) | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| US6235782B1 (en) | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| JP4049477B2 (ja) * | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| WO2000073281A1 (de) * | 1999-05-31 | 2000-12-07 | Discovery Technologies Ag | Antiviral und antitumoral wirksame thymin-derivate |
| JP4110347B2 (ja) * | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗ｈｉｖ剤 |
| US6906067B2 (en) * | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| ES2363766T3 (es) | 2002-08-21 | 2011-08-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibidores de nucleosidasas y fosforilasas de nucleosidos. |
| US20070275988A1 (en) * | 2003-09-05 | 2007-11-29 | Schramm Vern L | Transition state structure and inhibitors of thymidine phosphorylases |
| US7622580B2 (en) * | 2004-08-13 | 2009-11-24 | Xerox Corporation | Colorant compounds |
| US7211131B2 (en) * | 2004-08-13 | 2007-05-01 | Xerox Corporation | Phase change inks |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| PT1849470T (pt) * | 2005-01-26 | 2017-09-22 | Taiho Pharmaceutical Co Ltd | Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase |
| JP5058156B2 (ja) * | 2006-04-13 | 2012-10-24 | 大鵬薬品工業株式会社 | 炎症性腸疾患治療薬 |
| US8148381B2 (en) * | 2006-06-30 | 2012-04-03 | Taiho Pharmaceutical Co., Ltd. | Potentiator of radiation therapy |
| AU2008310734B2 (en) | 2007-10-10 | 2014-06-05 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
| TWI435725B (zh) * | 2007-10-11 | 2014-05-01 | Taiho Pharmaceutical Co Ltd | The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis |
| TWI429439B (zh) * | 2007-10-11 | 2014-03-11 | Taiho Pharmaceutical Co Ltd | And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient |
| PL2295414T3 (pl) * | 2008-06-03 | 2013-02-28 | Taiho Pharmaceutical Co Ltd | Związek uracylu o aktywności hamującej ludzką trifosfatazę deoksyurydyny lub jego sól |
| NZ590757A (en) | 2008-07-01 | 2014-05-30 | Univ Gifu | Novel imino derivative, process for production of the same, and pesticide comprising the same |
| JP2010202591A (ja) * | 2009-03-04 | 2010-09-16 | Hokkaido Univ | 増殖性疾患の内用放射線治療剤 |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| CN103732213A (zh) | 2011-06-07 | 2014-04-16 | 帕里昂科学公司 | 治疗方法 |
| TWI503122B (zh) | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| DK2979700T3 (da) | 2013-03-27 | 2019-01-21 | Taiho Pharmaceutical Co Ltd | Antitumormiddel, der indbefatter en lav irinotecanhydrochloridhydrat |
| NZ712584A (en) | 2013-03-27 | 2018-03-23 | Taiho Pharmaceutical Co Ltd | Antitumor agent including irinotecan hydrochloride hydrate |
| TWI595879B (zh) | 2013-05-17 | 2017-08-21 | Taiho Pharmaceutical Co Ltd | Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity |
| PT3012255T (pt) * | 2013-06-17 | 2021-11-30 | Taiho Pharmaceutical Co Ltd | Forma de cristal estável de cloridrato de tipiracilo e método de cristalização para o mesmo |
| WO2015034032A1 (ja) | 2013-09-06 | 2015-03-12 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| CN104744443A (zh) * | 2013-12-26 | 2015-07-01 | 江苏豪森药业股份有限公司 | 嘧啶二酮类化合物盐酸盐新晶型及其制备方法 |
| CN106333952A (zh) * | 2014-02-19 | 2017-01-18 | 齐鲁制药有限公司 | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 |
| CN104945384B (zh) * | 2014-03-25 | 2018-10-16 | 江苏豪森药业集团有限公司 | 5-氯-6-[(2-亚氨基-1-吡咯烷)甲基]-2,4(1h,3h)-嘧啶二酮或其盐的制备方法 |
| CN104945385A (zh) * | 2014-03-31 | 2015-09-30 | 江苏豪森药业股份有限公司 | Tipracil盐酸盐的新晶型及其制备方法 |
| NZ725067A (en) | 2014-04-04 | 2019-01-25 | Taiho Pharmaceutical Co Ltd | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer |
| CN106317028A (zh) * | 2015-11-03 | 2017-01-11 | 江苏悦兴药业有限公司 | 抗肿瘤药物盐酸替比拉西的制备方法及其关键中间体 |
| CN105906573A (zh) * | 2015-12-23 | 2016-08-31 | 嘉实（湖南）医药科技有限公司 | 一种替吡嘧啶中间体的制备方法 |
| AU2017205531B2 (en) | 2016-01-08 | 2021-05-13 | Les Laboratoires Servier | Anti-tumor agent containing immunomodulator and anti-tumor effect potentiator |
| JP6882205B2 (ja) | 2016-02-05 | 2021-06-02 | 大鵬薬品工業株式会社 | 重度腎機能障害を有する癌患者に対する治療方法 |
| US11654157B2 (en) | 2017-01-09 | 2023-05-23 | Shuttle Pharmaceuticals, Inc. | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation |
| CN106831607A (zh) * | 2017-02-14 | 2017-06-13 | 山东创新药物研发有限公司 | 一种6‑氯甲基尿嘧啶的合成方法 |
| CN106892902A (zh) * | 2017-03-01 | 2017-06-27 | 国药心制药有限公司 | 一种盐酸替匹嘧啶及其中间体6‑氯甲基尿嘧啶的合成方法 |
| TWI671072B (zh) | 2017-03-17 | 2019-09-11 | 法商施維雅藥廠 | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 |
| WO2019002407A1 (en) | 2017-06-28 | 2019-01-03 | Amneal Pharmaceuticals Company Gmbh | PROCESS FOR THE PREPARATION OF TIPIRACIL CHLORHYDRATE |
| US11149026B2 (en) * | 2017-09-07 | 2021-10-19 | Msn Laboratories Private Limited, R&D Center | Solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride and their processes for the preparation thereof |
| ES2987509T3 (es) * | 2017-11-02 | 2024-11-15 | Procos Spa | Proceso para la preparación de la forma cristalina III de clorhidrato de tipiracilo |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| WO2019124544A1 (ja) | 2017-12-22 | 2019-06-27 | 大鵬薬品工業株式会社 | トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法 |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2019171394A1 (en) | 2018-03-03 | 2019-09-12 | Natco Pharma Limited | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride |
| WO2020121334A1 (en) | 2018-12-15 | 2020-06-18 | Natco Pharma Limited | An improved process for the preparation of tipiracil hydrochloride and intermediates thereof |
| CN109796441B (zh) * | 2019-02-19 | 2020-10-16 | 北京民康百草医药科技有限公司 | 一种盐酸替比嘧啶的杂质a的制备方法 |
| CN114057697B (zh) * | 2020-08-07 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种替吡嘧啶中间体的制备方法 |
| AR127893A1 (es) | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820712A (en) * | 1986-08-27 | 1989-04-11 | Stichting Katholieke Universiteit | Sparsomycin (SC-RS) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (SC-RS) compounds |
| JPH0751567B2 (ja) * | 1989-09-29 | 1995-06-05 | 三菱化学株式会社 | ６―置換アシクロピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤 |
| KR0155168B1 (ko) * | 1989-09-29 | 1998-11-16 | 미우라 아끼라 | 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제 |
| JPH075570B2 (ja) * | 1990-03-29 | 1995-01-25 | 三菱化学株式会社 | ピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤 |
| CA2039039C (en) * | 1990-03-29 | 2001-05-15 | Tadashi Miyasaka | Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient |
| EP0763529B1 (en) * | 1995-03-29 | 2003-07-23 | Taiho Pharmaceutical Company Limited | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
-
1996
- 1996-03-28 EP EP96907693A patent/EP0763529B1/en not_active Expired - Lifetime
- 1996-03-28 KR KR1019960706628A patent/KR100424934B1/ko not_active Expired - Lifetime
- 1996-03-28 AU AU51216/96A patent/AU681321B2/en not_active Expired
- 1996-03-28 DK DK96907693T patent/DK0763529T3/da active
- 1996-03-28 JP JP08529175A patent/JP3088757B2/ja not_active Expired - Lifetime
- 1996-03-28 DE DE69629156T patent/DE69629156T2/de not_active Expired - Lifetime
- 1996-03-28 PT PT96907693T patent/PT763529E/pt unknown
- 1996-03-28 US US08/737,677 patent/US5744475A/en not_active Expired - Lifetime
- 1996-03-28 AT AT96907693T patent/ATE245631T1/de active
- 1996-03-28 CA CA002191340A patent/CA2191340C/en not_active Expired - Lifetime
- 1996-03-28 HU HU9603280A patent/HU227726B1/hu unknown
- 1996-03-28 WO PCT/JP1996/000828 patent/WO1996030346A1/ja not_active Ceased
- 1996-03-28 ES ES96907693T patent/ES2203683T3/es not_active Expired - Lifetime
- 1996-11-28 NO NO965083A patent/NO308033B1/no not_active IP Right Cessation
-
1998
- 1998-01-12 US US09/006,009 patent/US6159969A/en not_active Expired - Lifetime
-
1999
- 1999-12-09 US US09/457,668 patent/US6294535B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9603280A3 (en) | 2001-04-28 |
| WO1996030346A1 (en) | 1996-10-03 |
| HUP9603280A2 (hu) | 1998-01-28 |
| ATE245631T1 (de) | 2003-08-15 |
| US5744475A (en) | 1998-04-28 |
| CA2191340C (en) | 2001-04-17 |
| EP0763529B1 (en) | 2003-07-23 |
| ES2203683T3 (es) | 2004-04-16 |
| EP0763529A1 (en) | 1997-03-19 |
| DE69629156T2 (de) | 2004-05-06 |
| NO308033B1 (no) | 2000-07-10 |
| HU227726B1 (en) | 2012-01-30 |
| JP3088757B2 (ja) | 2000-09-18 |
| US6294535B1 (en) | 2001-09-25 |
| CA2191340A1 (en) | 1996-10-03 |
| NO965083L (no) | 1997-01-27 |
| AU5121696A (en) | 1996-10-16 |
| US6159969A (en) | 2000-12-12 |
| KR970703326A (ko) | 1997-07-03 |
| KR100424934B1 (ko) | 2004-07-27 |
| AU681321B2 (en) | 1997-08-21 |
| PT763529E (pt) | 2003-12-31 |
| EP0763529A4 (en) | 1998-07-08 |
| DE69629156D1 (de) | 2003-08-28 |
| NO965083D0 (no) | 1996-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0763529T3 (da) | Uracilderivater og antitumorvirkningspotentiator og antitumormiddel indeholdende samme | |
| DK0784054T3 (da) | 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister | |
| DE69118082D1 (de) | Imidazolderivate, starke und selektive Angiotensin-II-Rezeptor-Antagonisten | |
| TNSN04213A1 (en) | High drug load tablet | |
| DE69425162D1 (de) | 4,5-diaryloxazol-derivate | |
| ATE94534T1 (de) | Antiarrhythmische verbindungen. | |
| IL146309A0 (en) | Indole-type derivatives as inhibitors of p38 kinase | |
| IL99161A0 (en) | Novel substituted guanidine derivatives,their preparation and use | |
| ATE402174T1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| PT628311E (pt) | Derivado de xantina com actividade antidepressiva | |
| DK0591528T3 (da) | Pyrazolo[1,5-a]pyrimidinderivat og antiinflammatorisk middel, der indeholder dette | |
| ATE79380T1 (de) | 2-substituierte-e-kondensierte(1,2,4>triazolo(1,5-c>pyrimidine, pharmazeutische zubereitungen und ihre verwendung. | |
| ATE101181T1 (de) | Anti-krebs-verbindungen. | |
| HUT62582A (en) | Process for producing pyrimidine nucleoside derivatives and pharmaceutical compositions comprising same as active ingredient | |
| PT884051E (pt) | Inibidores de metasteses cancerosas contendo derivados de uracilo | |
| DE3878268D1 (de) | Heterocyclische verbindungen. | |
| ATE182331T1 (de) | Oxazolidone derivative als monoamine- oxidaseinhibitoren | |
| DK640489D0 (da) | C63-amidderivater af 34-de-(acetylglucosaminyl)-34-deoxy-teicoplaniner | |
| DE69329385D1 (de) | Thiazolin-derivate | |
| MX9300423A (es) | Derivados heterociclicos. | |
| DE69426620D1 (de) | Antidepressiva | |
| EP0379737A3 (en) | Dihydropyridine derivatives for the treatment of angiospasm | |
| TH36111A (th) | อนุพันธ์ไพแรโซล | |
| KR950032159A (ko) | 티아디아지논 유도체 |